PKPD

Mepolizumab exposure and blood eosinophils

A coupled subcutaneous or intravenous PK/PD model linking mepolizumab absorption and distribution to concentration-dependent suppression and turnover of circulating eosinophils.

Explore and simulate

Therapeutic: Mepolizumab, Nucala
Target: IL5, IL-5
Disease: Asthma

Biological model

A coupled subcutaneous or intravenous PK/PD model linking mepolizumab absorption and distribution to concentration-dependent suppression and turnover of circulating eosinophils.

Biological schematic for Mepolizumab exposure and blood eosinophils — Biology-first schematic of the model structure.

Model details

A coupled subcutaneous or intravenous PK/PD model linking mepolizumab absorption and distribution to concentration-dependent suppression and turnover of circulating eosinophils.

Modeled states

AUC ug day mLug*day/mL

Modeled dynamic state for auc ug day ml.
A central mgmg

Modeled dynamic state for a central mg.
A depot mgmg

Modeled dynamic state for a depot mg.
A peripheral mgmg

Modeled dynamic state for a peripheral mg.
blood eosinophils GI LGcell/L

Modeled dynamic state for blood eosinophils gi l.
elapsed time dayday

Modeled dynamic state for elapsed time day.

Key readouts

Mepolizumab concentrationunknown

Model-derived readout for mepolizumab concentration.
Blood eosinophilsGcell/L

Model-derived readout for blood eosinophils.
Eosinophil inhibitionunknown

Model-derived readout for eosinophil inhibition.
Cumulative exposureug*day/mL

Model-derived readout for cumulative exposure.
A central mgmg

Model-derived readout for a central mg.

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

Starting configuration

12.5 mg SC every 4 weeks, three doses

How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression? Explore this intervention regimen through Mepolizumab concentration, Blood eosinophils, Eosinophil inhibition, Cumulative exposure. This is a mechanistic product exploration, not a paper-result reproduction.

Questions to explore

How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression?

Starting result

This result reflects the starting settings. Run your changes to update it.

This scenario result is temporarily unavailable.

Model inputs

Five scientist-facing controls at most.

CL iv L day Model parameter controlling cl iv l day. L/dayVc iv L Model parameter controlling vc iv l. LKA 1 day Model parameter controlling ka 1 day. 1/dayIC50 ng mL Model parameter controlling ic50 ng ml. ng/mLIMAX fraction Model parameter controlling imax fraction. dimensionless

Compare a parameter

How does one model input change the response?

How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression?

Parameter to compare

CL iv L day

Model parameter controlling cl iv l day.

Exploratory range around the default value.

Low High Points

5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.

Interpret with care

Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.

Review the server-confirmed fixed price before starting the comparison.

Comparative response

End-of-window response across the selected parameter values.

Choose an exploratory range around the default, review the fixed price, and run the comparison.

Scientific reference

Supporting publication

Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab

Int. Journal of Clinical Pharmacology and Therapeutics